Clinical trial

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

NCT01870609

Study summary

ClinicalTrials.gov

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention defactinib (VS-6063) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2013-09-01

PhasePHASE2

Conditions

Malignant Pleural Mesotheliomaverified · MONDO: malignant pleural mesothelioma

Interventions

defactinib (VS-6063)DRUG

PlaceboDRUG

Sponsors & collaborators

Verastem, Inc.lead sponsor

Mapped research locations

MadridSpain2 BarcelonaSpain2 LondonUnited Kingdom2 New YorkNew York, United States1 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 TorontoOntario, Canada1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 ClevelandOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01870609 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.